Novo Nordisk CEO Lars Sørensen: An Interview With "The Pink Sheet"
Executive Summary
Novo Nordisk AS turned in a strong financial showing in 2010, with sales up 13%, and the Danish company has been riding a wave of positive investor sentiment. The launch of the once-daily GLP-1 analogue Victoza (liraglutide) in the U.S. in the early part of the year helped to drive sales, but its modern insulins portfolio also continues to perform well.
You may also be interested in...
Obesity Drug Developers Go With The Gut: R&D Hopes Focus On Locally Acting Agents
Developers remaining in the daunting weight loss space are pinning their hopes on a new wave of locally acting drugs with the hope that gut-selective mechanisms will show better efficacy combined with fewer safety concerns than the three centrally acting obesity candidates recently rebuffed by FDA.
Obesity Drug Developers Go With The Gut: R&D Hopes Focus On Locally Acting Agents
Developers remaining in the daunting weight loss space are pinning their hopes on a new wave of locally acting drugs with the hope that gut-selective mechanisms will show better efficacy combined with fewer safety concerns than the three centrally acting obesity candidates recently rebuffed by FDA.
Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market
SHANGHAI - Denmark's Novo Nordisk AS announced March 15 that its human glucagon-like peptide-1 (GLP-1) analogue Victoza (liraglutide) was granted regulatory approval from China's State FDA, and plans to launch the anti-diabetes drug in the second half of this year